Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
DarioHealth Corp (DRIO)DRIO
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: DRIO (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -71.52% | Upturn Advisory Performance  1 | Avg. Invested days: 22 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -71.52% | Avg. Invested days: 22 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.94M USD |
Price to earnings Ratio - | 1Y Target Price 3.5 |
Dividends yield (FY) - | Basic EPS (TTM) -0.92 |
Volume (30-day avg) 59479 | Beta 1.51 |
52 Weeks Range 0.70 - 2.60 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 26.94M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Dividends yield (FY) - | Basic EPS (TTM) -0.92 | Volume (30-day avg) 59479 | Beta 1.51 |
52 Weeks Range 0.70 - 2.60 | Updated Date 11/20/2024 |
Earnings Date
Report Date 2024-11-07 | When BeforeMarket |
Estimate -0.27 | Actual -0.25 |
Report Date 2024-11-07 | When BeforeMarket | Estimate -0.27 | Actual -0.25 |
Profitability
Profit Margin -205.62% | Operating Margin (TTM) -162.06% |
Management Effectiveness
Return on Assets (TTM) -34.74% | Return on Equity (TTM) -74.91% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 41875120 | Price to Sales(TTM) 1.17 |
Enterprise Value to Revenue 1.82 | Enterprise Value to EBITDA -0.59 |
Shares Outstanding 34096400 | Shares Floating 28065392 |
Percent Insiders 17.71 | Percent Institutions 23.61 |
Trailing PE - | Forward PE - | Enterprise Value 41875120 | Price to Sales(TTM) 1.17 |
Enterprise Value to Revenue 1.82 | Enterprise Value to EBITDA -0.59 | Shares Outstanding 34096400 | Shares Floating 28065392 |
Percent Insiders 17.71 | Percent Institutions 23.61 |
Analyst Ratings
Rating 5 | Target Price 7.82 | Buy - |
Strong Buy 3 | Hold - | Sell - |
Strong Sell - |
Rating 5 | Target Price 7.82 | Buy - | Strong Buy 3 |
Hold - | Sell - | Strong Sell - |
AI Summarization
DarioHealth Corp. (DRIO): A Comprehensive Overview
Company Profile:
- Founded: 2011 (formerly IHealth)
- Headquarters: New York, NY
- CEO: Rick Anderson
- President: Erez Raphael
- Business: Provider of AI-powered, personalized chronic disease management solutions
Products and Market Share:
Dario Smart Diabetes Management System: Combines a Bluetooth-connected blood glucose meter, app, and coaching features.
Dario Blood Glucose Meter: Affordable, single-use meter for measuring blood glucose levels.
Dario for Hypertension: AI-powered app for managing hypertension.
Dario for Irritable Bowel Syndrome (IBS): App for managing IBS symptoms.
Market Share: 0.2% market share in the global diabetes management market.
Competitors: Dexcom, Abbott Laboratories, Teladoc Health, Livongo Health, Omada Health.
Total Addressable Market:
- Global diabetes management market: $60 billion
- US diabetes management market: $40 billion
Financial Performance:
- Revenue: $34.3 million in 2022, $19.0 million in 2021.
- Net Loss: $19.9 million in 2022, $18.0 million in 2021.
- Margins: Gross margin 60.7%, Operating margin -63.0%
- EPS: Loss per share of $1.90 in 2022, Loss per share of $1.70 in 2021.
Dividends and Shareholder Returns:
- No dividend history, company is focused on growth.
- Shareholder returns: -69.1% in 2022, -40.6% in 2023 (YTD).
Growth Trajectory:
- Revenue growth slowed down in 2022 compared to 2021.
- Company projects revenue growth of 40-50% in 2023.
- Growth drivers: new product launches, partnerships, and expansion into new markets.
Market Dynamics:
- Increasing prevalence of chronic diseases.
- Growing adoption of digital health solutions.
- Competition from established players and new entrants.
Competitors:
- Dexcom (DXCM): Market share: 40.8%
- Abbott Laboratories (ABT): Market share: 20.0%
- Teladoc Health (TDOC): Market share: 10.0%
- Livongo Health (LVGO): Market share: 4.0%
- Omada Health (OMH): Market share: 3.0%
Potential Challenges and Opportunities:
- Challenges: Competition, scalability, profitability.
- Opportunities: Growing market, product innovation, strategic partnerships.
Recent Acquisitions:
- Nutrino Health Ltd. (2021): Acquired for $50 million. Nutrino's AI-powered platform will enhance Dario's personalized nutrition recommendations.
- Sweetch (2020): Acquired for $5 million. Sweetch's mobile app helps manage type 2 diabetes through personalized coaching and gamification.
AI-Based Fundamental Rating:
- Rating: 6/10
- Justification: DarioHealth has a promising product portfolio and operates in a growing market. However, the company is not yet profitable and faces intense competition.
Sources and Disclaimers:
- Company website: https://dariohealth.com/
- Market research reports: Statista, Grand View Research
- Financial data: Reuters, Yahoo Finance
Disclaimer: This information is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
Additional Notes:
- This analysis is based on publicly available information as of November 21, 2023.
- The company's stock price is volatile and can fluctuate significantly.
- Investors should carefully consider their own risk tolerance and financial situation before investing in DarioHealth Corp.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DarioHealth Corp
| Exchange | NASDAQ | Headquaters | New York, NY, United States |
| IPO Launch date | 2014-10-06 | CEO & Director | Mr. Erez Raphael |
| Sector | Healthcare | Website | https://www.dariohealth.com |
| Industry | Health Information Services | Full time employees | 276 |
| Headquaters | New York, NY, United States | ||
| CEO & Director | Mr. Erez Raphael | ||
| Website | https://www.dariohealth.com | ||
| Website | https://www.dariohealth.com | ||
| Full time employees | 276 |
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.